Molecular-Targeting Revolution Advances into Renal Cancer: Is Sutent® the New Gold Standard for Metastatic Disease?

Author: Adis International Limited  

Publisher: Adis International

ISSN: 1176-3469

Source: Pharmaceutical & Diagnostic Innovation, Vol.4, Iss.7, 2006-07, pp. : 8-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract